Healthcare experts reviewing an IVF centre business plan
← All insights MARKET INTELLIGENCE · OCTOBER 2026

Nepal's IVF Market: Unmet Fertility Needs, Investment Feasibility and Strategic Opportunities

A research-led view of market structure, affordability, regional opportunities and the investment conditions that matter.

Healthcare experts reviewing an IVF centre business plan

Nepal may offer a selective opportunity for fertility-care development, but the evidence points to a fragmented market, affordability constraints and material regulatory questions. The white paper’s central recommendation is to investigate hospital-integrated models and defer irreversible IVF capital commitments until procedure-specific legal permissions and patient-volume feasibility are established.

Decision in one sentence

Nepal is a potentially attractive but operationally fragmented fertility-care market; hospital-integrated business models merit investigation, while IVF capital commitments should be deferred until applicable oocyte-retrieval restrictions and licence conditions are clarified in writing.

1. Nepal IVF market: the evidence snapshot

The October 2026 white paper synthesizes publicly accessible secondary sources through 27 October 2026 and an illustrative investment model. It is a research discussion paper, not an audited demand estimate, legal opinion, engineering bill of quantities or investment recommendation for a specific project.

29.16M Population reported in the 2021 census
51 ART centres identified in a 2024–25 survey
35 Centres reported as fully operational
66.7% Identified centres located in Kathmandu Valley

The survey included 34 operational centres. The paper notes that 24 of the 34 surveyed centres reported no more than 20 cycles per month. This suggests a varied operating landscape and a need to verify actual activity, laboratory capacity and staffing rather than relying on advertised locations alone.

2. Demand, treatment affordability and what is not yet known

The paper reports Nepal’s total fertility rate at 2.1 births per woman in the 2022 Demographic and Health Survey, down from 4.6 in 1996. It also references the WHO estimate that 17.5% of adults globally experience infertility during their lifetime. That global figure is not a Nepal-specific prevalence estimate and should not be presented as one.

Crucially, the study does not claim a definitive national IVF market size. A validated national annual IVF-cycle denominator was not available in the reviewed evidence. Medical need, treatment-seeking demand, clinically indicated IVF and paid cycles captured by a particular centre are different measures.

For affordability context, the paper cites median annual household income of NPR 383,389 for 2022/23 and indicative published IVF treatment prices of NPR 300,000–500,000. An illustrative NPR 350,000 treatment bill is approximately 91% of that historical median annual household income. This is an affordability signal, not a statement about every patient’s finances or current household income.

3. Regional opportunities: where to investigate

The paper proposes an initial desk-based screening of three hospital-partnership corridors. These are diligence priorities, not statistically ranked opportunities or proof of underserved demand.

Butwal / Rupandehi Test whether a host hospital can demonstrate sufficient infertility consultations and referral activity.
Bharatpur / Chitwan Assess whether demand is incremental or already served by existing centres.
Pokhara / Kaski Evaluate whether a quality-led proposition can attract financially realizable cycles.

Biratnagar / Morang, Nepalgunj / Banke and Kathmandu Valley are also included in the broader location-screening table. Site selection should consider a practical 90–120 minute catchment, gynaecology throughput, referral leakage, host-hospital quality, provider utilization and affordability — not district population alone.

4. Regulatory clarity is a hard investment gate

The white paper describes a material unresolved issue concerning the scope and status of interim restrictions on removal and storage of women’s eggs. It reports that Nepal’s Supreme Court issued an interim order on 19 August 2025 and that reporting in April–May 2026 indicated continuing uncertainty. The authors state that they had not obtained a definitive October 2026 court disposition or regulator-issued scope clarification.

Important investment caution

Because autologous IVF ordinarily involves egg retrieval, a proposed project must not assume routine retrieval services are legally permitted. The precise order, procedural scope and current status must be reviewed by Nepalese counsel alongside the applicable ministry standards. Procedure-specific written clearance should precede capital commitment.

The paper also flags professional registration and permissions for foreign clinicians and embryologists, institutional approvals, patient-consent and traceability protocols, and cross-border investment / technology-transfer questions. A previous institutional licence should not be assumed to resolve every procedure-specific requirement.

5. Which operating model should be explored first?

The preferred first-entry architecture in the paper is a Nepalese licensed hospital as clinical operator, a suitably registered fertility / embryology team as clinical and laboratory delivery partners, and Oospheere as a clearly contracted business and technical adviser. Clinical judgement and patient consent must remain under the appropriate licensed medical leadership.

  • Hospital-integrated IVF unit: potential use of existing clinicians, facilities and emergency support, with partner-governance and licence dependencies.
  • Clinician + hospital joint venture: aligned local leadership and infrastructure, but more complex capital, profit-sharing and exit terms.
  • Central lab + licensed satellites: possible regional convenience, subject to strict inter-site coordination and licensing.
  • Standalone centre: greater autonomy but higher fixed-cost and demand-capture risk; not the preferred first choice in the paper.

6. Clinical operations and quality governance

The recommended programme is a comprehensive couple-based fertility service with progressive, evidence-based evaluation, people-centred care and affordability in mind. The paper highlights clinical eligibility and counselling, laboratory environmental qualification and traceability, distinct outcome denominators, safety monitoring, patient grievance systems, written package inclusions and workforce continuity.

Centre performance should not be judged on “positive pregnancy rates” alone. Retrievals, fertilisation, clinical pregnancy, miscarriage, multiple pregnancy and live birth should be tracked with clear denominators and case-mix context. Patient welfare, laboratory integrity and avoidance of unnecessary treatment should override commercial cycle targets.

7. Illustrative economics — scenario, not forecast

The white paper includes a brownfield hospital-integrated illustration denominated in Nepalese rupees. It models NPR 350 lakh in initial investment and a base-case contribution of NPR 1.85 lakh per cycle equivalent. At modelled Year 1 fixed expenditure of NPR 160 lakh, the EBITDA break-even threshold is approximately 87 annual cycle equivalents. These are scenario assumptions, not audited centre economics, a vendor BOQ or an investment payback calculation.

Read the numbers carefully

The five-year aggregate modelled EBITDA is approximately NPR 3.56 crore, near the assumed NPR 3.50 crore startup investment. The paper explicitly cautions that this does not demonstrate investment payback: free cash flow differs due to working capital, financing, tax and capital maintenance.

8. A practical 90-day diligence roadmap

Days 1–20 Retrieve the court order; consult regulators; obtain company and investment-law advice.
Days 21–40 Conduct market interviews and competitor mapping in Butwal, Bharatpur and Pokhara.
Days 41–60 Audit hospital clinical capacity, infrastructure and referral volumes.
Days 61–75 Validate supplier quotations, staffing costs and realized pricing.
Days 76–90 Review governance, downside cash flow and the proceed / redesign / stop decision.

Conclusion: research first, commit capital later

The white paper’s final position is a go for research, advisory and compliant quality-improvement opportunities; a conditional go for hospital-partnership development; and no irreversible IVF capital commitment until procedure-specific legal clearance and patient-volume feasibility are established.

For Oospheere, near-term opportunities include pre-feasibility studies, hospital project structuring, technical design, embryology quality support and operational turnaround services. Any expansion into management contracting or equity should follow legal and commercial validation.

Selected references and source documents

  1. National Statistics Office, Nepal — National Population and Housing Census 2021 .
  2. Nepal Demographic and Health Survey 2022 — DHS fact sheet .
  3. World Health Organization (2023) — One in six people globally affected by infertility .
  4. Shrestha, S.M. (2025) — Current Status and Challenges of Assisted Reproductive Technology Services in Nepal .
  5. National Statistics Office — Nepal Living Standards Survey IV 2022/23.
  6. Vardhan IVF Nepal — IVF cost in Nepal: published patient guide .
  7. Maya IVF Clinic — IVF pricing and package details .
  8. Gandhi & Associates — Overview of Nepal Infertility Management Service Operation Standards, 2082 .
  9. The Kathmandu Post — Supreme Court interim order reporting, 19 August 2025 .
  10. The Kathmandu Post — Unauthorised IVF consultation camp reporting, 16 April 2026 .
  11. Radio Nepal — Health minister on additional IVF and surrogacy legislation, 18 September 2026 .
  12. Department of Industry, Nepal — Foreign investment rules and thresholds .
  13. Embassy of India in Kathmandu — Handbook for Indian Investors: Investing in Nepal .
  14. World Health Organization (2025) — Guideline for the prevention, diagnosis and treatment of infertility .
Source & disclaimer

Article adapted from Nepal's IVF Market: Unmet Fertility Needs, Investment Feasibility and Strategic Opportunities , Oospheere IVF Services Pvt. Ltd., October 2026, Version 1.0, authored for strategic discussion by Dr Madhur Hamine. All forward-looking volumes and margins are scenarios requiring local validation. This article is an informational summary and not legal, clinical, financial or investment advice.

Selected references cited in the white paper: Nepal National Population and Housing Census 2021; Nepal DHS 2022; WHO infertility prevalence report (2023); Shrestha (2025) ART-centre survey; Nepal Living Standards Survey IV 2022/23; Nepal regulatory and court-order reporting; WHO infertility guideline (2025).

Exploring an IVF business opportunity?

Start with a feasibility-led conversation with Oospheere.

Talk to our team